Evidence map›Paper›PMID 31806376›Full record

ArticleBiochemical and biophysical research communications2020

FLCN alteration drives metabolic reprogramming towards nucleotide synthesis and cyst formation in salivary gland.

Yasuhiro Isono, Mitsuko Furuya, Tatsu Kuwahara, Daisuke Sano, Kae Suzuki, Ryosuke Jikuya, Taku Mitome, Shinji Otake, Takashi Kawahara, Yusuke Ito and 13 more

Open access · greenAbstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 8 institutions in 2 countries.

Yasuhiro IsonoDepartment of Otorhinolaryngology, Yokohama, 236-0004, Japan.
Mitsuko FuruyaDepartment of Molecular Pathology, Yokohama, 236-0004, Japan.
Tatsu KuwaharaDepartment of Otorhinolaryngology, Yokohama, 236-0004, Japan.
Daisuke SanoDepartment of Otorhinolaryngology, Yokohama, 236-0004, Japan.
Kae SuzukiDepartment of Urology, Yokohama, 236-0004, Japan.
Ryosuke JikuyaDepartment of Urology, Yokohama, 236-0004, Japan.
Taku MitomeDepartment of Urology, Yokohama, 236-0004, Japan.
Shinji OtakeDepartment of Urology, Yokohama, 236-0004, Japan.
Takashi KawaharaDepartment of Urology, Yokohama, 236-0004, Japan.
Yusuke ItoDepartment of Urology, Yokohama, 236-0004, Japan.
Kentaro MuraokaDepartment of Urology, Yokohama, 236-0004, Japan.
Noboru NakaigawaDepartment of Urology, Yokohama, 236-0004, Japan.
Yayoi KimuraAdvanced Medical Research Center, Yokohama City University, Yokohama, 236-0004, Japan.
Masaya BabaInternational Research Center for Medical Sciences, Kumamoto University, Kumamoto, 860-0811, Japan.
Kiyotaka NagahamaDepartment of Pathology, Graduate School of Medical Sciences, Kyorin University, Mitaka, Tokyo, 181-8611, Japan.
Hiroyuki TakahataDepartment of Pathology, Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan.
Ichiro SaitoDepartment of Pathology, Tsurumi University School of Dental Medicine, Yokohama, 230-8501, Japan.
Laura S SchmidtUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
W Marston LinehanUrologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Tatsuhiko KodamaLaboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, University of Tokyo, Tokyo, 153-8904, Japan.
Masahiro YaoDepartment of Urology, Yokohama, 236-0004, Japan.
Nobuhiko OridateDepartment of Otorhinolaryngology, Yokohama, 236-0004, Japan. Electronic address: noridate@yokohama-cu.ac.jp.
Hisashi HasumiDepartment of Urology, Yokohama, 236-0004, Japan. Electronic address: hasumi@yokohama-cu.ac.jp.
National Institutes of Health · USYokohama University of Pharmacy · JPKumamoto University · JPKyorin University · JPShikoku Cancer Center · JPThe University of Tokyo · JPTsurumi University · JPYokohama City University Medical Center · JP

Funding

Urologic Oncology Branch Consult CoreZIDBC011092 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$41.0M
Molecular Therapeutics of Kidney Cancer: MET Gene and BHD GeneZIABC011043 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$20.9M
Clinical Studies of the Molecular Genetic Basis of Kidney CancerZIABC011028 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.9M
Clinical Nursing and Data Management CoreZIDBC011089 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LINEHAN, WILLIAM MARSTON · 2009 to 2025
$17.4M
CCR NIH HHS HHSN261200800001CIntramural NIH HHS ZIA BC011043Intramural NIH HHS ZID BC011092NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

FLCN is a tumor suppressor gene which controls energy homeostasis through regulation of a variety of metabolic pathways including mitochondrial oxidative metabolism and autophagy. Birt-Hogg-Dubé (BHD) syndrome which is driven by germline alteration of the FLCN gene, predisposes patients to develop kidney cancer, cutaneous fibrofolliculomas, pulmonary cysts and less frequently, salivary gland tumors. Here, we report metabolic roles for FLCN in the salivary gland as well as their clinical relevance. Screening of salivary glands of BHD patients using ultrasonography demonstrated increased cyst formation in the salivary gland. Salivary gland tumors that developed in BHD patients exhibited an upregulated mTOR-S6R pathway as well as increased GPNMB expression, which are characteristics of FLCN-deficient cells. Salivary gland-targeted Flcn knockout mice developed cytoplasmic clear cell formation in ductal cells with increased mitochondrial biogenesis, upregulated mTOR-S6K pathway, upregulated TFE3-GPNMB axis and upregulated lipid metabolism. Proteomic and metabolite analysis using LC/MS and GC/MS revealed that Flcn inactivation in salivary gland triggers metabolic reprogramming towards the pentose phosphate pathway which consequently upregulates nucleotide synthesis and redox regulation, further supporting that Flcn controls metabolic homeostasis in salivary gland. These data uncover important roles for FLCN in salivary gland; metabolic reprogramming under FLCN deficiency might increase nucleotide production which may feed FLCN-deficient salivary gland cells to trigger tumor initiation and progression, providing mechanistic insight into salivary gland tumorigenesis as well as a foundation for development of novel therapeutics for salivary gland tumors.

Indexed as

AdultAnimalsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsCystsFemaleGene OntologyGlycolysisHumansMaleMice, KnockoutMiddle AgedNucleotidesOrganelle BiogenesisPentose Phosphate PathwayProto-Oncogene ProteinsSalivary GlandsBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBhd protein, mouseFLCN protein, humanNucleotidesProto-Oncogene ProteinsTcfe3 protein, mouseTOR Serine-Threonine KinasesTumor Suppressor ProteinsBirt-hogg-dubé (BHD) syndromeFLCNMitochondriamTOR-TFE3 pathwaySalivary gland tumor

Identifiers

PMID31806376
PMCPMC8195446
OpenAlexW2993936267

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.